Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study()

BACKGROUND: Omalizumab has demonstrated efficacy as an add-on therapy in Chinese patients with moderate-to-severe allergic asthma. This post-hoc analysis assessed the potential predictors for the efficacy of omalizumab in these patients. METHODS: A post-hoc analysis was performed on a Phase III, ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Wang, Changzheng, Liu, Chuntao, Kang, Jian, Kong, Lingfei, Huang, Yijiang, Liu, Shuang, Huang, Mao, Wang, Lu, Fogel, Robert, Jaumont, Xavier, Yang, Jing, Zhong, Nanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461112/
https://www.ncbi.nlm.nih.gov/pubmed/34611470
http://dx.doi.org/10.1016/j.waojou.2020.100469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461112/
https://www.ncbi.nlm.nih.gov/pubmed/34611470
http://dx.doi.org/10.1016/j.waojou.2020.100469

Ejemplares similares